|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||||||||||
  Acta Psychiatrica ScandinavicaVolume 107 Issue 5, Pages 344 - 350 Published Online: 12 May 2003 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 102K) | Related Articles | Citation Tracking  Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study Copyright 2003 Blackwell Munksgaard KEYWORDS risperidone • olanzapine • compliance • weight gain • schizophrenia Søholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.
Acta Psychiatr Scand 2003: 107: 344–350. © Blackwell Munksgaard 2003. ABSTRACTObjective: To evaluate the long-term effectiveness of the second generation antipsychotics, risperidone and olanzapine on hospitalization, clinical response, and adherence to therapy after switching from conventional antipsychotics or clozapine in a naturalistic setting of schizophrenic patients. Method: Data were registered for periods of identical duration before and after switching. Results: Fifty-seven patients were included. Mean study period was 3.1 ± 0.2 years. Mean number of in-patient days after switching declined by 78% of the level before switching (P=0.0002). There was no significant differences in ratio responders/non-responders between the subgroups. The number of patients with extrapyramidal symptoms (EPS) was significantly reduced after switching. However, intolerable weight gain led to a lack of adherence to therapy in 18% of the olanzapine-treated patients. Conclusion: Long-term treatment with the second generation antipsychotics, risperidone and olanzapine significantly improved the clinical outcome. However, weight gain may be a significant reason for discontinuation of treatment and reducing the long-term adherence to therapy. Accepted for publication November 11, 2002 | 
|
|
| ||||||||||||||||
|
|
|||||||||||||||||||
 | Personality and Mental Health |
| |
